Conference Reports for NATAP

Back

ID Week 2024 October 16-19 Los Angeles, California     Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024 - (11/06/24)   Implementation and Uptake of Long-acting Injectable PrEP at Atlanta VA Healthcare System - (10/24/24)   Implementation and Uptake of Long-acting Injectable PrEP at Atlanta VA Healthcare System - (10/24/24)   Opportunities for PrEP Awareness and Engagement: A Survey among Cisgender Women Seeking Healthcare in the US - (10/24/24)   Improving HIV Pre-exposure Prophylaxis (PrEP) among Transgender Individuals - (10/24/24)   Integrating PrEP Services into a Gynecology Clinic in Alabama: A Qualitative Analysis of Key Determinants - (10/24/24)   Concerns and opinions of people currently or previously on oral and long acting injectable forms of HIV preexposure prophylaxis (PrEP) - (10/24/24)   Predictors of Undetectable HDV RNA 48 Weeks After Completion of Finite Treatment With Bulevirtide and Pegylated-Interferon Alpha-2a - (10/24/24)   Efficacy and Safety of Bulevirtide Monotherapy for Chronic Hepatitis Delta in Patients With and Without Cirrhosis: Results From the Week 144 Interim Analysis of a Phase 3 Randomized Study - (10/24/24)   Should HCV Be Treated in Pregnant Persons? - (10/24/24)   Efficacy and Safety of B/F/TAF in Black Adults With HIV Who Are Treatment Naïve: 5-Year Follow-Up From Two Phase 3 Studies - (10/23/24)   Trends in HIV-Related Mortality Among People of Reproductive Potential in the United States HIV Deaths Plunge in Reproductive-Age US Women From 1999 to 2020 - Mark Mascolini (10/23/24)   Antiretroviral prophylaxis to prevent perinatal HIV infection in Medicaid-insured infants, 2009-2021: Over Half of HIV Infections in First Year of Life Reflect No Postnatal HIV Prophylaxis...majority Black Race - Mark Mascolini (10/23/24)   Effects of Antiretroviral Resistance on Outcomes and Healthcare Resource Use of People with HIV in the United States and Europe: a real-world survey - (10/23/24)   Treatment Patterns and Healthcare Resource Utilization of Heavily Treatment Experienced People With HIV - (10/23/24)   Impact of Pharmacoenhancers on the Pharmacokinetics and Safety of Lenacapavir in People with HIV - (10/23/24)   Extrapolating Expected Efficacy, Safety, and Pharmacokinetics (PK) of Dolutegravir/Lamivudine (DTG/3TC) in Pregnant People Living With HIV-1 From Pregnancy Data With Combination DTG and/or 3TC Antiretroviral Therapies - (10/23/24)   Extrapolating Expected Efficacy, Safety, and Pharmacokinetics (PK) of Dolutegravir/Lamivudine (DTG/3TC) in Pregnant People Living With HIV-1 From Pregnancy Data With Combination DTG and/or 3TC Antiretroviral Therapies - (10/23/24)   Characteristics of Women Initiating CAB+RPV LA in the OPERA Cohort - (10/23/24)   LAI CAB/RPV plus SC LEN Effective in PWH with Poor Long-term Adherence and INSTI or NNRTI RAMs - (10/23/24)   Assessment of Failures of Long-Acting Cabotegravir and Rilpivirine in a Real-World Treatment Setting - (10/23/24)   PWH Mortality Declined. Disparities Blacks, Socially Vulnerable, Older PWHL: CDC Analysis - Mark Mascolini (10/23/24)   Metformin reduces the risk of Long COVID or Death over 6 months in an Emulated Target Trial of Primarily Omicron-infected Adults without Diabetes or Prediabetes New-User, Active-Comparator Analysis - (10/23/24)   Obeldesivir for the Treatment of COVID-19 in People With Risk Factors for Progression to Severe Disease: The BIRCH Study - (10/22/24)   Obeldesivir for Treatment of COVID-19 in Adults and Adolescents Without Risk Factors for Progression to Severe Disease: The OAKTREE Study - (10/22/24)   Incidence of Long COVID Symptoms During the Year Post Admission Among Patients Hospitalized for COVID-19; for Immunocompromised - (10/22/24)   Obeldesivir Reduced SARS-CoV-2 Infectious Titers in the BIRCH Phase 3 Clinical Trial - (10/22/24)   Paxlovid Cuts Severe COVID Risk in People With Prior Infection or Vaccination - Mark Mascolini (10/22/24)   Efficacy and Safety of B/F/TAF in Treatment-Naïve People With HIV Aged ≥ 50 Years: 5-Year Follow-Up From Two Phase 3 Studies - (10/22/24)   Breast Cancer (BC) and Colorectal Cancer (CRC) Screenings among Persons with HIV (PWH): The Role of Individual and System-Level Factors on Screening Completion - (10/22/24)   Comorbidities and Healthcare Resource Utilization Among People With HIV: Real-World Data From a Large Israeli Healthcare Provider - (10/22/24)   T-cell Immune Exhaustion and the Atherogenic Index of Plasma in People Living with HIV on Antiretroviral Therapy - (10/22/24)   Comparison of Renal Outcomes by Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) Containing Regimens for Prevention, and Treatment of HIV and/or HBV Treatment: A Systematic Literature Review and Meta-Analysis - (10/22/24)   High HBV Screening Rate in US Veterans Group With HIV - Mark Mascolini (10/22/24)   HBV HIV Screening Among HIV+ US Veterans Administration - (10/22/24)   Trajectories of Newly Initiated Pre-Exposure Prophylaxis (PrEP) Use among Priority Populations with Unmet Needs for PrEP in the USA - (10/21/24)   Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Data from Trio Health Cohort - (10/21/24)   Missed opportunities for HIV Prevention and Treatment in People Hospitalized with Serious Injection Related Infections: The CHOICE+ Cohort - (10/21/24)   Week 26 Interim Analysis of Implementation and Delivery of Long-Acting Injectable Cabotegravir for PrEP in a Community Pharmacy Setting - (10/21/24)   Cabotegravir Long-Acting for Pre-Exposure Prophylaxis (PrEP): Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort - (10/21/24)   Social Determinants of Health and Side Effects Significantly Predict Pre-Exposure Prophylaxis (PrEP) Preferences for Every 2 Month Long-Acting Injectable vs. Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic - (10/21/24)   Change in Healthcare Professionals' Identification, Counseling, and Adherence With Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women's Health, Primary Care, and Infectious Diseases Sites: Findings From the EBONI Study - (10/21/24)   PrEP Decision Factors: a CHORUS Healthcare Professional Survey - (10/21/24)   Changes in Renal Function After Switching from Emtricitabine/Tenofovir Disoproxil Fumarate to Emtricitabine/Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis (PrEP): A Real-World Study - (10/21/24)   Update on Lenacapavir for PrEP: Results from the Interim Analyses of PURPOSE 1 and PURPOSE 2 - (10/21/24)   Over 80% Adhere to Long-Acting CAB+RPV Despite Prior Non-Adherence - Mark Mascolini (10/21/24)   People With HIV in the United States (US) Switching to Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) From Oral Antiretroviral Therapy (ART) Have Numerous Real-World Benefits, Including High Adherence and Treatment Satisfaction - (10/21/24)   Long-acting Injectable HIV Treatment in Individuals with Adherence Challenges: - (10/21/24)   Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir - (10/20/24)   Similar Efficacy, Safety and CD4 T-cell Increase up to Week 96 Observed With Fostemsavir (FTR)-Based Regimens in the BRIGHTE Study and Dolutegravir (DTG)-Based Regimens in the VIKING-3 Study in Individuals With Multidrug-Resistant (MDR) HIV-1 - (10/20/24)   CD4 T-cell, CD4/CD8 Ratio Improvement and a General Reduction in Inflammatory Biomarkers With Low-Level Viremia (LLV) up to Week 192 With Fostemsavir (FTR)-Based Regimens in Individuals With Multidrug-Resistant (MDR) HIV-1 - (10/20/24)   Racial/Ethnic Disparities of Renal Outcomes in People With HIV on Tenofovir Alafenamide-Based Antiretroviral Therapy Regimens in the Real World - (10/20/24)   Lenacapavir Sustains HIV Control and Keeps Boosting CD4s Through 3 Years - Mark Mascolini (10/20/24)   Optimizing 2-Drug Switch HBV Screening: pilot intervention to increase HBV screening - (10/20/24)   Long-Acting Subcutaneous Lenacapavir in People with HIV-1 Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study - (10/20/24)   Pharmacokinetics and Safety of GS-1720 Following Multiple Ascending Doses in a Phase 1a Study in People Without HIV-1 - (10/20/24)   PAIRED - PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): A diverse sample of people with HIV-1 (PWH) reporting high treatment satisfaction, good adherence, and high quality of life - (10/20/24)   ViiV HEALTHCARE SHOWS MORE THAN 99% EFFECTIVENESS IN REAL-WORLD STUDIES FOR APRETUDE (CABOTEGRAVIR LONG-ACTING), THE ONLY APPROVED LONG-ACTING HIV PREP, IN DATA PRESENTED AT IDWEEK 2024 - (10/16/24)